Global Cancer Diagnostics Device Market Size By Type (Companion Diagnostics, Molecular Diagnostics), By Application (Lung, Breast), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Diagnostics Device Market was valued at USD 56.2 billion in 2023 and is expected to surpass USD 98.7 billion by 2031, registering a CAGR of 7.3% during the forecast period 2023-2031.

The market is driven by the rising prevalence of cancer worldwide, increasing demand for early detection, and advancements in diagnostic technologies. Cancer diagnostics devices play a crucial role in identifying malignancies at early stages, enabling effective treatment planning and improving patient outcomes. The growing adoption of AI-based diagnostic tools, liquid biopsy technologies, and next-generation sequencing (NGS) methods is further fueling market expansion.

Drivers:

1. Rising Cancer Prevalence Globally

Cancer remains a leading cause of death worldwide, with millions of new cases diagnosed each year. The increasing burden of cancer is driving the demand for effective diagnostic solutions.

2. Technological Advancements in Diagnostic Devices

The development of AI-powered imaging systems, molecular diagnostics, and liquid biopsy methods is enhancing the accuracy, speed, and efficiency of cancer detection.

3. Growing Demand for Early Detection

Early diagnosis significantly improves survival rates. Governments and healthcare organizations are investing in awareness programs and screening initiatives, boosting the demand for cancer diagnostic devices.

Restraints:

1. High Cost of Advanced Diagnostic Devices

Many cancer diagnostic tools, such as NGS and PET-CT scanners, require significant investment, making them less accessible in low-income regions.

2. Limited Availability of Skilled Professionals

Operating sophisticated cancer diagnostic devices requires skilled professionals. A shortage of trained personnel, especially in developing regions, is a major challenge.

Opportunity:

1. Expansion in Emerging Markets

The rising healthcare expenditure and improving infrastructure in developing countries provide significant opportunities for cancer diagnostics device manufacturers.

2. Growing Adoption of AI and Machine Learning

AI-based diagnostics are revolutionizing cancer detection by increasing accuracy and reducing human error, presenting growth opportunities for companies investing in AI-powered solutions.

3. Personalized Medicine and Liquid Biopsy

The growing shift toward personalized medicine and the increasing adoption of liquid biopsy techniques, which offer non-invasive cancer detection, are expected to drive market growth.

Market by Device Type Insights:

Imaging Devices (MRI, PET-CT, Mammography, Ultrasound)

Biopsy Instruments

Molecular Diagnostics Devices (NGS, PCR-based tests)

Immunohistochemistry (IHC) Devices

Point-of-Care Diagnostic Devices

Among these, Imaging Devices held the largest market share in 2023 due to their widespread use in cancer screening and diagnosis.

Market by End-Use Insights:

Hospitals & Diagnostic Laboratories

Cancer Research Institutes

Ambulatory Care Centers

Home Care Settings

Hospitals & Diagnostic Laboratories accounted for the largest share due to the high volume of cancer diagnostics performed in hospital settings.

Market by Regional Insights:

North America: The largest market in 2023, driven by advanced healthcare infrastructure, a high prevalence of cancer, and early adoption of new diagnostic technologies.

Europe: Significant market growth due to favorable reimbursement policies and increased investments in cancer research.

Asia-Pacific: Expected to witness the fastest growth due to improving healthcare infrastructure, increasing cancer incidence, and rising awareness.

Latin America & Middle East & Africa: Growing adoption of cancer diagnostics due to government initiatives and increasing healthcare spending.

Competitive Scenario:

Key players in the Global Cancer Diagnostics Device Market include:

GE Healthcare

Siemens Healthineers

F. Hoffmann-La Roche Ltd

Abbott Laboratories

Thermo Fisher Scientific Inc.

Philips Healthcare

Illumina, Inc.

Hologic, Inc.

Qiagen N.V.

PerkinElmer, Inc.

These companies focus on product innovation, strategic collaborations, and technological advancements to maintain their market position.

Scope of Work – Global Cancer Diagnostics Device Market

Report Metric Details

Market Size (2023) USD 56.2 billion

Projected Market Size (2031) USD 98.7 billion

CAGR (2023-2031) 7.3%

Key Segments by Device Type Imaging Devices, Biopsy Instruments, Molecular Diagnostics Devices, Immunohistochemistry (IHC) Devices, Point-of-Care Devices

Key Segments by End-Use Hospitals & Diagnostic Laboratories, Cancer Research Institutes, Ambulatory Care Centers, Home Care Settings

Leading Region North America

Key Players GE Healthcare, Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Philips Healthcare, Illumina, Inc., Hologic, Inc., Qiagen N.V., PerkinElmer, Inc.

Key Market Developments:

March 2023: Siemens Healthineers introduced an AI-powered MRI system for cancer detection, enhancing imaging accuracy and speed.

July 2023: Roche launched a next-generation sequencing (NGS) platform for early-stage cancer detection.

November 2023: GE Healthcare partnered with leading oncology centers to integrate AI into cancer diagnostic imaging.

FAQs:

1. What is the current market size of the Global Cancer Diagnostics Device Market?

The market was valued at USD 56.2 billion in 2023 and is expected to grow significantly over the forecast period.

2. What is the major growth driver of the Global Cancer Diagnostics Device Market?

The major growth driver is the rising prevalence of cancer globally, along with advancements in diagnostic technologies and the increasing demand for early cancer detection.

3. Which is the largest region during the forecast period in the Global Cancer Diagnostics Device Market?

North America is the largest region due to its advanced healthcare infrastructure and high adoption of innovative cancer diagnostic technologies.

4. Which segment accounted for the largest market share in the Global Cancer Diagnostics Device Market?

Imaging Devices accounted for the largest market share due to their widespread use in cancer screening and detection.

5. Who are the key market players in the Global Cancer Diagnostics Device Market?

Key players include GE Healthcare, Siemens Healthineers, Roche, Abbott Laboratories, Thermo Fisher Scientific, Philips Healthcare, Illumina, Hologic, Qiagen, and PerkinElmer.

This report provides a detailed analysis of the Global Cancer Diagnostics Device Market, including market trends, drivers, restraints, opportunities, segmentation, and competitive landscape to help stakeholders make informed business decisions.